Thursday, December 12, 2024, 7:15 PM – 9:15 PM CT (8:15 PM – 10:15 PM ET) | San Antonio, Texas

Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of Metastatic Breast Cancer

Part 3 of a 3-Part CME Satellite Symposium Series in Partnership with the 2024 San Antonio Breast Cancer Symposium®

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Program Schedule — Central Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Educational Dinner Meeting
Buffet will open at 7:00 PM CT.

Meeting Room
Grand Ballroom G-M (Third Floor)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
Erika Hamilton, MD
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Kevin Kalinsky, MD, MS
Professor
Department of Hematology and Medical Oncology
Emory University School of Medicine
Director, Division of Medical Oncology
Director, Glenn Family Breast Center
Winship Cancer Institute of Emory University
Atlanta, Georgia

Ian E Krop, MD, PhD
Associate Cancer Center Director for Clinical Research
Director, Clinical Trials Office
Yale Cancer Center
New Haven, Connecticut


Joyce O’Shaughnessy, MD
Celebrating Women Chair in
Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Dallas, Texas

Sara M Tolaney, MD, MPH
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Puma Biotechnology Inc. This is not an official program of the San Antonio Breast Cancer Symposium®.
Program Schedule — Central Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Educational Dinner Meeting
Buffet will open at 7:00 PM CT.

MODULE 1: Optimizing the Care of Patients with HER2-Positive Metastatic Breast Cancer (mBC)

  • Clinical factors, such as prior HER2-directed therapy, symptomatology, disease-free interval, and sites and extent of metastases affecting the selection and sequencing of therapy for patients with HER2-positive mBC
  • Published research findings from key studies, such as DESTINY-Breast02, DESTINY-Breast03 and HER2CLIMB, establishing the efficacy of trastuzumab deruxtecan (T-DXd) and tucatinib/trastuzumab/capecitabine for patients with HER2-positive mBC
  • Design, eligibility criteria, and key efficacy and safety findings from the Phase III HER2CLIMB-02 trial of tucatinib in combination with T-DM1
  • Incidence of brain metastases in patients with HER2-positive mBC; published research documenting the CNS activity of T-DXd and tucatinib/trastuzumab/capecitabine
  • Designs, eligibility criteria and key endpoints of ongoing studies, such as DESTINY-Breast07, DESTINY-Breast09, HER2CLIMB-04 and HER2CLIMB-05, attempting to further define the role of T-DXd and tucatinib in the management of HER2-positive mBC
  • Long-term findings with and optimal integration of neratinib/capecitabine, margetuximab/chemotherapy, and lapatinib-based approaches into treatment regimens for patients with progressive HER2-positive mBC
  • Other promising agents and strategies for advanced HER2-positive breast cancer

MODULE 2: Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)

  • Long-term efficacy and safety findings with pembrolizumab/chemotherapy for previously untreated PD-L1-positive mTNBC; optimal integration into patient care
  • Scientific rationale for targeting TROP2 in breast cancer; mechanistic similarities and differences between sacituzumab govitecan and datopotamab deruxtecan (Dato-DXd)
  • Design, eligibility criteria and key efficacy and safety findings from the Phase III ASCENT trial of sacituzumab govitecan for previously treated mTNBC; FDA approval and optimal integration into management algorithms
  • Biological rationale for combining TROP2-targeted antibody-drug conjugates (ADCs) with immune checkpoint inhibitor therapy for TNBC
  • Ongoing Phase III studies evaluating sacituzumab govitecan alone or combined with an immune checkpoint inhibitor earlier in the treatment course
  • Early data with and ongoing evaluation of Dato-DXd alone or in combination with an immune checkpoint inhibitor for mTNBC
  • Role of T-DXd in treatment for HR-negative, HER2-low mBC; optimal sequencing opposite sacituzumab govitecan and other available treatment options
  • Long-term data guiding the use of PARP inhibitors for patients with mTNBC and germline BRCA mutations

MODULE 3: Integrating Novel Agents and Approaches into the Management of Endocrine-Resistant HR-Positive mBC

  • Key clinical determinants of endocrine resistance in HR-positive mBC
  • Design, eligibility criteria and key efficacy and safety findings from the Phase III TROPiCS-02 trial of sacituzumab govitecan for previously treated HR-positive, HER2-negative mBC
  • FDA approval and optimal sequencing of sacituzumab govitecan for HR-positive, HER2-negative mBC
  • Design, eligibility criteria and key efficacy and safety findings of the Phase III TROPION-Breast01 trial comparing Dato-DXd to chemotherapy for previously treated HR-positive, HER2-negative mBC; potential clinical role
  • Available data and appropriate sequencing of T-DXd opposite other standard therapies for previously treated HR-positive, HER2-low advanced breast cancer
  • Design, eligibility criteria and emerging efficacy findings from the Phase III DESTINY-Breast06 trial assessing T-DXd versus chemotherapy for HR-positive, HER2-low, and HER2-ultralow mBC
  • Rationale for targeting HER3 in mBC; available research findings with and structural components and mechanism of action of patritumab deruxtecan (HER3-DXd)

MODULE 4: Tolerability Considerations with the Use of Commonly Employed Therapies

  • Comparative tolerability/toxicity profiles of sacituzumab govitecan, T-DXd, Dato-DXd and HER3-DXd for mBC
  • Spectrum, incidence and severity of common and unique adverse events (AEs) associated with different ADCs for mBC
  • Frequency and severity of toxicities with sacituzumab govitecan for patients with reduced UGT1A1 activity; approach to AE mitigation, monitoring and treatment
  • Monitoring and management of acute chemotherapy-like AEs, such as cytopenias and gastrointestinal events, seen with ADCs
  • Recommended algorithms for mitigating more serious AEs, such as interstitial lung disease and left ventricular dysfunction, with T-DXd and other ADCs
  • Management of oral mucositis/stomatitis, ocular toxicities and other treatment-related AEs with Dato-DXd

MODULE 5: Other Important Care Considerations for Patients with mBC

  • Importance of patient self-advocacy and role of individual desires in the metastatic decision-making process
  • Promising investigational strategies, interesting clinical trials in progress and benefits of trial participation for patients with mBC
  • Importance of increasing diversity, equity and inclusion in clinical trials and ongoing initiatives to facilitate this goal
  • Available research findings with early palliative care and effect on clinical outcomes
  • Benefits associated with alternative therapeutic approaches and role in breast cancer management

Target Audience
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider biological, patient, psychosocial and treatment-related factors to personalize the selection and sequencing of therapy for metastatic breast cancer (mBC).
  • Review and use published research findings to effectively inform the selection and sequencing of available therapeutic agents and regimens for patients with HER2-positive mBC.
  • Review published research data supporting the use of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for patients with metastatic triple-negative breast cancer (mTNBC), and use this information to make appropriate treatment recommendations.
  • Evaluate published research findings, clinical factors (eg, age, performance status, prior therapeutic exposure, HER2-low status) and personal preferences in the selection and sequencing of available therapeutic agents for patients with PD-L1-negative mTNBC or those with PD-L1-positive mTNBC who experience disease progression on front-line chemoimmunotherapy.
  • Discuss available research establishing the efficacy of PARP inhibitors in patients with mBC harboring BRCA or other homologous recombination repair pathway mutations, and identify appropriate candidates for treatment with these agents.
  • Define endocrine resistance in patients with HR-positive mBC, and integrate available nonhormonal therapies into the management of relapsed/refractory disease.
  • Review published Phase III research documenting the efficacy of TROP2-directed antibody-drug conjugates for mBC to determine the current and potential clinical applicability of this approach.
  • Assess the biological rationale for, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies in development for mBC.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

Dr HamiltonConsulting Agreements (Paid to Institution): Accutar Biotechnology Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Circle Pharma, Daiichi Sankyo Inc, Ellipses Pharma, Entos Pharmaceuticals, Fosun Pharma USA Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Jefferies LLC, Johnson & Johnson Pharmaceuticals, Lilly, Medical Pharma Services SRO, Mersana Therapeutics Inc, Novartis, Olema Oncology, Pfizer Inc, Stemline Therapeutics Inc, Tempus, Theratechnologies, Tubulis, Zentalis Pharmaceuticals; Contracted Research (Paid to Institution): AbbVie Inc, Accutar Biotechnology Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics, Akesobio Australia Pty Ltd, Amgen Inc, Aravive Inc, ARS Pharmaceuticals, Artios Pharma Limited, Arvinas, AstraZeneca Pharmaceuticals LP, AtlasMedx Inc, BeiGene Ltd, Black Diamond Therapeutics Inc, Bliss Biopharmaceutical (Hangzhou) Co Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Compugen, Context Therapeutics, Cullinan Therapeutics, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Deciphera Pharmaceuticals Inc, Duality Biologics, eFFECTOR Therapeutics Inc, Eisai Inc, Ellipses Pharma, Elucida Oncology Inc, EMD Serono Inc, Fochon Pharmaceuticals, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Harpoon Therapeutics, Hutchison MediPharma, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Inspirna, InventisBio, Jacobio Pharmaceuticals Group Co Ltd, Karyopharm Therapeutics, K-Group Beta, Kind Pharmaceuticals LLC, Leap Therapeutics Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Merck, Mereo BioPharma, Mersana Therapeutics Inc, Merus, Myriad Genetic Laboratories Inc, Novartis, NuCana, Olema Oncology, Oncothyreon, ORIC Pharmaceuticals, Orinove Inc, Orum Therapeutics, Pfizer Inc, PharmaMar, Pieris Pharmaceuticals Inc, Pionyr Immunotherapeutics, Plexxikon Inc, Prelude Therapeutics, ProfoundBio, Radius Health Inc, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Repertoire Immune Medicines, Seagen Inc, Sermonix Pharmaceuticals, Shattuck Labs, Stemline Therapeutics Inc, Sutro Biopharma, Syndax Pharmaceuticals, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Tolmar, Transcenta, Treadwell Therapeutics, Verastem Inc, Zenith Epigenetics, Zymeworks Inc; Nonrelevant Financial Relationships: Dana-Farber Cancer Institute, Verascity Science. Dr KalinskyAdvisory Committees: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, Cullinan Therapeutics, Cyclacel Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Eisai Inc, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Prelude Therapeutics, RayzeBio, Regor Therapeutics Group, Seagen Inc; Data and Safety Monitoring Board/Committee: Merck; Stock Options/Stock — Public Companies: Grail Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Pfizer Inc (spouse prior employment). Dr KropAdvisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Novartis, Seagen Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group; Contracted Research: MacroGenics Inc, Pfizer Inc; Data and Safety Monitoring Boards/Committees: Merck, Novartis, Seagen Inc. Dr O'ShaughnessyAdvisory Committees and Consulting Agreements: Agendia Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BioNTech SE, Byondis, Caris Life Sciences, Daiichi Sankyo Inc, DAVA Oncology, Eisai Inc, Exact Sciences Corporation, Fishawack Health, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Merck, Mersana Therapeutics Inc, Novartis, Ontada, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Tempus, Veru Inc. Dr TolaneyConsulting Agreements: Aadi Bioscience, Artios Pharma Limited, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioNTech SE, Blueprint Medicines, Bristol Myers Squibb, Circle Pharma, Cullinan Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Hengrui Therapeutics Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Lilly, Menarini Group, Merck, Natera Inc, Novartis, Pfizer Inc, Reveal Genomics, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Sumitovant Biopharma, SystImmune Inc, Tango Therapeutics, Umoja Biopharma, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer Inc, Seagen Inc, Stemline Therapeutics Inc; Travel Support: BioNTech SE, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Lilly, Pfizer Inc, Sanofi.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSeraTherapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Puma Biotechnology Inc.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom G-M (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2024 San Antonio Breast Cancer Symposium is taking place.

 
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Antonio, you must also be registered to attend the 2024 San Antonio Breast Cancer Symposium®.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.